Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral cavity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    315 result(s) found for: Oral cavity. Displaying page 8 of 16.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2021-000580-78 Sponsor Protocol Number: EMPAtia Start Date*: 2022-02-02
    Sponsor Name:The Children’s Memorial Health Institute
    Full Title: "The assessment of effectiveness and safeness of utilizing empagliflozin in the treatment of neutropenia of patients suffering from glycogenolysis type Ib"
    Medical condition: neutropenia and / or abnormal neutrophil function in glycogenosis I b
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004592-74 Sponsor Protocol Number: HOLOGENE7(HTA-HG7-01) Start Date*: 2016-06-01
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: PROSPECTIVE, OPEN LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR...
    Medical condition: RDEB is characterized by generalized skin blistering, erosions, crusts, atrophic scarring, onychodystrophy and loss of nails, mutilating pseudosyndactyly of hands and feet, as well as oral cavity l...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002886-20 Sponsor Protocol Number: DHNS2013-01/MOHN01 Start Date*: 2014-01-30
    Sponsor Name:UMC St Radboud
    Full Title: A phase Ib-II study of the combination of cetuximab and methotrexate in recurrent or metastatic squamous cell carcinoma of the head and neck. A study of the Dutch Head and Neck Society.
    Medical condition: Recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003669-32 Sponsor Protocol Number: GONO-Sancuso Start Date*: 2020-07-03
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: GRANISETRON TRANSDERMAL SYSTEM (GTDS) IN PREVENTING NAUSEA AND VOMITING INDUCED BY CISPLATIN-BASED CHEMOTHERAPY AND CONCURRENT RADIOTHERAPY FOR HEAD AND NECK CANCER
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10046311 Upper respiratory tract neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022548-19 Sponsor Protocol Number: TP-434-P2-cIAI-1 Start Date*: 2011-05-09
    Sponsor Name:Tetraphase Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of 2 Dose Regimens of TP-434 Compared with Ertapenem in Adult...
    Medical condition: Community-acquired complicated intra-abdominal infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BG (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004627-33 Sponsor Protocol Number: GSN000400 Start Date*: 2022-02-03
    Sponsor Name:Genkyotex Suisse SA
    Full Title: A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability, and Effects on Tumour Biomarkers of the NOX1/4 Inhibitor Setanaxi...
    Medical condition: Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001439-74 Sponsor Protocol Number: 20062080 Start Date*: 2007-09-04
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
    Medical condition: Advance Squamous Cell Carcinoma of the Head and Neck
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) HU (Completed) DE (Completed) ES (Completed) IT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002676-87 Sponsor Protocol Number: CA209-9TM Start Date*: 2018-02-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Elig...
    Medical condition: Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002466-39 Sponsor Protocol Number: CFTSp032 Start Date*: 2014-01-24
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A randomised placebo-controlled trial of synchronous NIMorazole versus RADiotherapy alone in patients with locally advanced head and neck squamous cell carcinoma not suitable for synchronous chemot...
    Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2019-003114-13 Sponsor Protocol Number: PACEACE Start Date*: 2020-01-31
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: A multicenter, single arm study
    Medical condition: Recurrent and/or metastatic head and neck cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000582-39 Sponsor Protocol Number: GEN205 Start Date*: 2008-09-18
    Sponsor Name:Genmab A/S
    Full Title: An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcino...
    Medical condition: Non-Curable Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) CZ (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004936-13 Sponsor Protocol Number: GORTEC_2018-01 Start Date*: 2020-05-26
    Sponsor Name:GORTEC
    Full Title: A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN)
    Medical condition: Squamous cell carcinoma treated by primary surgery Stage III, stage IV (American Joint Committee on Cancer 7th edition) Oral cavity, oropharynx, hypopharynx or larynx
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002163-22 Sponsor Protocol Number: NANORAY-312 Start Date*: 2022-07-13
    Sponsor Name:Nanobiotix SA
    Full Title: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for platinum-based Chemotherapy-ineligible Elderly P...
    Medical condition: Locally Advanced Head & Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Prematurely Ended) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000898-39 Sponsor Protocol Number: SSGXXII Start Date*: 2014-12-19
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study.
    Medical condition: gastrointestinal stromal tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002263-99 Sponsor Protocol Number: 209229 Start Date*: 2020-05-12
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squ...
    Medical condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) IE (Completed) SE (Completed) DE (Prematurely Ended) PL (Completed) DK (Completed) AT (Prematurely Ended) NO (Completed) HU (Prematurely Ended) GR (Completed) PT (Completed) ES (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-003130-90 Sponsor Protocol Number: CLYS228X2202 Start Date*: 2018-08-08
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, controlled, evaluator-blinded, multi-center study to evaluate LYS228 pharmacokinetics, clinical response, safety, and tolerability in patients with complicated intra-abdominal infection
    Medical condition: complicated Intra-Abdominal Infections (cIAI)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10056570 Intra-abdominal infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003921-40 Sponsor Protocol Number: 2016IF002 Start Date*: 2017-07-21
    Sponsor Name:University Hospital of South Manchester NHS Foundation Trust
    Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis
    Medical condition: Chronic Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000154164 10003488 Aspergillosis LLT
    20.0 100000015649 10003493 Aspergillus fumigatus bronchopulmonary infection LLT
    20.0 100000154164 10003494 Aspergillus fumigatus infection LLT
    20.0 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 100000015649 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024425-20 Sponsor Protocol Number: Esperanz-002 Start Date*: 2011-03-14
    Sponsor Name:Leiden University Medical Centre
    Full Title: Phase III Randomized Double-blind Cross-over trial of Supersaturated Calcium-phosphate rinse (Caphosol®) versus NaCl 0.9% in the relief of Oral Mucositis in renal cell carcinoma, hepatocellular car...
    Medical condition: oral mucositis in renal cell carcinoma, hepatocellular carcinoma, and gastrointestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028127 Mucositis LLT
    12.1 10042128 Stomatitis LLT
    12.1 10042128 Stomatitis PT
    12.1 10031009 Oral pain LLT
    12.1 10031009 Oral pain PT
    12.1 10013911 Dysgeusia LLT
    12.1 10013911 Dysgeusia PT
    12.1 10013950 Dysphagia LLT
    12.1 10013950 Dysphagia PT
    12.1 10013781 Dry mouth LLT
    12.1 10013781 Dry mouth PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000639-13 Sponsor Protocol Number: A0661142 Start Date*: 2005-10-10
    Sponsor Name:Pfizer Ltd
    Full Title: An open-label, multi-center trial of azithromycin pharmacokinetics in sinus aspirate and serum following oral administration of either a 500 mg immediate-release (IR) once-daily 3 day regimen or a ...
    Medical condition: Acute bacterial sinusitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10060841 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002257-23 Sponsor Protocol Number: 62063 Start Date*: 2009-01-26
    Sponsor Name:European Organization for Research and Treatment of Cancer
    Full Title: A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.
    Medical condition: Metastatic gastro-intestinal stromal tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062427 Gastrointestinal stromal tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:38:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA